- ViiV Healthcare announced new data on long-acting injectables for HIV at IAS 2025.
- Studies focus on effectiveness, patient preferences, and real-world application.
- Insights presented at the conference aim to improve HIV treatment and prevention strategies.
ViiV Healthcare, a leader in HIV treatment and prevention, highlighted the positive impact of its long-acting injectable regimen for HIV at the International AIDS Society 2025 Conference in Kigali, Rwanda. The data showcases the success of Vocabria + Rekambys, branded as Cabenuva in the US, Canada, and Australia, and its application in broad populations.
The studies presented at IAS 2025 reveal significant findings, including the preferences of treatment-naive adults for the CAB+RPV LA (cabotegravir + rilpivirine long-acting) injection after rapid viral suppression with Dovato (DTG/3TC). Additionally, real-world effectiveness, adherence, and satisfaction data from various cohort studies such as COMBINE-2 and CARLOS underscore the benefits of this treatment approach.
Moreover, implementation data on Apretude (cabotegravir long-acting) for HIV pre-exposure prophylaxis (PrEP) highlights the drug's acceptability and benefits in real-world settings, especially among men who have sex with men, transgender men, and Black women. Interim results from the Positive Perspectives study emphasize the importance of joint decision-making and its correlation with treatment satisfaction and health outcomes.
ViiV Healthcare's commitment to advancing HIV care is reinforced by the comprehensive data presented, aiming to offer greater flexibility and choice beyond daily oral therapies to meet the evolving needs of people living with HIV.
